KMT2A and diffuse large B-cell lymphoma: In accordance with previous reports, ARID1A (45%), KMT2A (32%), ANKRD11 (32%), NOTCH2 (32%), and KMT2D (30%) were recurrently mutated in our EBV + DLBCL (NOS) cohort, albeit at partially elevated frequencies compared with EBV-negative DLBCL.